Drug Profile
Inarigivir soproxil - F-star Therapeutics
Alternative Names: GS 9992; Inarigivir; SB-9200Latest Information Update: 23 Mar 2023
Price :
$50
*
At a glance
- Originator BioHEP Technologies
- Developer F-star Therapeutics; Gilead Sciences; National Institutes of Health (USA); Spring Bank Pharmaceuticals
- Class Antivirals; Hepatoprotectants; Nucleotides; Small molecules
- Mechanism of Action DDX58 protein stimulants; Immunomodulators; NOD2 protein agonists; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis C
Highest Development Phases
- Discontinued Dengue; Hepatitis B; Hepatitis C; Hepatitis D; HIV infections; Japanese encephalitis; Norovirus infections; Respiratory syncytial virus infections; Tuberculosis; West Nile virus infections
Most Recent Events
- 23 Mar 2023 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in Australia (PO)
- 23 Mar 2023 Discontinued - Phase-I for Hepatitis C (Treatment-naive) in New Zealand (PO)
- 23 Mar 2023 Discontinued - Preclinical for Hepatitis C in USA (PO)